Back to top
Abbott Laboratories (ABT)
(Real Time Quote from BATS)
$117.54 USD
117.54
1,739,526
+1.14 (0.98%)
Updated Sep 16, 2024 03:04 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
View All Zacks #1 Ranked Stocks
Cash flow Statements
Fiscal Year End for Abbott Laboratories falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Cash Flow From Operations, Investments & Financial Activities |
|||||
| Net Income (Loss) | 5,723.00 | 6,933.00 | 7,071.00 | 4,495.00 | 3,687.00 |
| Depreciation/Amortization & Depletion | 3,243.00 | 3,267.00 | 3,538.00 | 3,327.00 | 3,014.00 |
| Net Change from Assets/Liabilities | -2,475.00 | -1,519.00 | -771.00 | -892.00 | -1,331.00 |
| Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Activities | 770.00 | 900.00 | 695.00 | 971.00 | 766.00 |
| Net Cash From Operating Activities | 7,261.00 | 9,581.00 | 10,533.00 | 7,901.00 | 6,136.00 |
| Property & Equipment | -2,202.00 | -1,777.00 | -1,885.00 | -2,177.00 | -1,638.00 |
| Acquisition/ Disposition of Subsidiaries | -837.00 | 48.00 | -53.00 | 16.00 | -122.00 |
| Investments | -116.00 | -33.00 | -96.00 | -73.00 | -82.00 |
| Other Investing Activities | 22.00 | 22.00 | 26.00 | 19.00 | 27.00 |
| Net Cash from Investing Activities | -3,133.00 | -1,740.00 | -2,008.00 | -2,215.00 | -1,815.00 |
Uses of Funds
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|---|
| Issuance (Repurchase) of Capital Stock | -1,060.00 | -3,628.00 | -2,044.00 | -158.00 | -420.00 |
| Issuance (Repayment) of Debt | -2,496.00 | -746.00 | -44.00 | -52.00 | -1,599.00 |
| Increase (Decrease) Short-Term Debt | 21.00 | 47.00 | -204.00 | 2.00 | 0.00 |
| Payment of Dividends & Other Distributions | -3,556.00 | -3,309.00 | -3,202.00 | -2,560.00 | -2,270.00 |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -11.00 | 0.00 |
| Net Cash from Financing Activities | -7,091.00 | -7,636.00 | -5,494.00 | -2,779.00 | -4,289.00 |
| Effect of Exchange Rate Changes | -23.00 | -122.00 | -70.00 | 71.00 | -16.00 |
| Net Change In Cash & Equivalents | -2,986.00 | 83.00 | 2,961.00 | 2,978.00 | 16.00 |
| Cash at Beginning of Period | 9,882.00 | 9,799.00 | 6,838.00 | 3,860.00 | 3,844.00 |
| Cash at End of Period | 6,896.00 | 9,882.00 | 9,799.00 | 6,838.00 | 3,860.00 |
| Diluted Net EPS | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 |
Fiscal Year End for Abbott Laboratories falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
| 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|---|
| Cash Flow From Operations, Investments & Financial Activities |
|||||
| Net Income (Loss) | 2,527.00 | 1,225.00 | 5,723.00 | 4,129.00 | 2,693.00 |
| Depreciation/Amortization & Depletion | 1,610.00 | 805.00 | 3,243.00 | 2,430.00 | 1,606.00 |
| Net Change from Assets/Liabilities | -989.00 | -561.00 | -2,475.00 | -951.00 | -630.00 |
| Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Operating Activities | -163.00 | -444.00 | 770.00 | -1,385.00 | -1,323.00 |
| Net Cash From Operating Activities | 2,985.00 | 1,025.00 | 7,261.00 | 4,223.00 | 2,346.00 |
| Property & Equipment | -931.00 | -398.00 | -2,202.00 | -1,447.00 | -887.00 |
| Acquisition/ Disposition of Subsidiaries | 1.00 | 0.00 | -837.00 | -837.00 | -786.00 |
| Investments | 49.00 | -28.00 | -116.00 | -45.00 | -7.00 |
| Other Investing Activities | 3.00 | 1.00 | 22.00 | 20.00 | 5.00 |
| Net Cash from Investing Activities | -878.00 | -425.00 | -3,133.00 | -2,309.00 | -1,675.00 |
Uses of Funds
| 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|---|
| Issuance (Repurchase) of Capital Stock | -82.00 | -92.00 | -1,060.00 | -835.00 | -889.00 |
| Issuance (Repayment) of Debt | 203.00 | 0.00 | -2,496.00 | -1,446.00 | -1.00 |
| Increase (Decrease) Short-Term Debt | -170.00 | -127.00 | 21.00 | -90.00 | -29.00 |
| Payment of Dividends & Other Distributions | -1,918.00 | -957.00 | -3,556.00 | -2,668.00 | -1,780.00 |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash from Financing Activities | -1,967.00 | -1,176.00 | -7,091.00 | -5,039.00 | -2,699.00 |
| Effect of Exchange Rate Changes | -49.00 | -36.00 | -23.00 | -48.00 | -19.00 |
| Net Change In Cash & Equivalents | 91.00 | -612.00 | -2,986.00 | -3,173.00 | -2,047.00 |
| Cash at Beginning of Period | 6,896.00 | 6,896.00 | 9,882.00 | 9,882.00 | 9,882.00 |
| Cash at End of Period | 6,987.00 | 6,284.00 | 6,896.00 | 6,709.00 | 7,835.00 |
| Diluted Net EPS | 0.74 | 0.70 | 0.91 | 0.82 | 0.78 |